Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-01-25
2005-01-25
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S238100, C514S012200, C514S802000, C530S380000
Reexamination Certificate
active
06846484
ABSTRACT:
The invention provides fusion toxins that contain one or more regions of diphtheria toxin and a portion of urokinase-type plasminogen activator, as well as the nucleic acids that encode the fusion toxins and methods of using the fusion toxins.
REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4831112 (1989-05-01), Kobayashi et al.
patent: 5208021 (1993-05-01), Johnson et al.
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5709843 (1998-01-01), Reisner
patent: 5720720 (1998-02-01), Laske et al.
patent: 5728383 (1998-03-01), Johnson et al.
patent: 5792458 (1998-08-01), Johnson et al.
patent: 5894018 (1999-04-01), Davila et al.
patent: 6001329 (1999-12-01), Buchsbaum et al.
patent: WO 9426308 (1994-11-01), None
patent: WO 9613599 (1996-05-01), None
patent: WO 0004926 (2000-02-01), None
Morishita et al (Nucleic Acids symposium series, 1996, vol. 35, pp. 291-292).*
Baty et al (Molecular Microbiology, 1988, vol. 2, pp. 807-811).*
Olsnes et al (Journal of Biological Chemistry, 1982, vol. 257, pp. 13263-13270).*
Greenfield et al (Science, 1987, vol. 238, pp. 536-539).*
el Kouhen et al (European Journal of Biochemistry, 1993, vol. 214, pp. 635-639).*
Geoff et al (Protein engineering, 1997, vol. 10, suppl. p. 5).*
Bouveret et al (Molecular Microbiology, 1997, vol. 23, pp. 909-920).*
Lacy et al (Journal of Molecular Biology, 1999, vol. 291, pp. 1091-1104).*
Wiedlocha et al (Cancer research, 1991, vol. 51, pp. 916-920).*
GenBank Accession No. E01560.
GenBank Accession No. K01722.
Collier and Kandel, “Structure and Activity of Diphtheria Toxin,”J. Biol. Chem., 1971, 246(5):1496-1503.
Collier, “Structure and Activity of Diphtheria Toxin,”ADP-Ribosylation Reactions—Biology and Medicine, 1982, Academic Press, New York, Chapter 34, pp. 575-592.
Davis et al., “Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991,”J. Neurosurg., 1998, 88:1-10.
Fabbrini et al., “The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated,”Faseb J., 1997, 11:1169-1176.
Greenfield et al., “Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage β,”Proc. Natl. Acad. Sci. USA, 1983, 80:6853-6857.
Kreitman, “Immunotoxins in cancer therapy,”Curr. Opin. Immunol., 1999, 11:570-578.
Laske et al., “Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors,”Nature Medicine, 1997, 3(12):1362-1368.
Marshall, “A New Phase in the War on Cancer,”Science, 1995, 267:1412-1415.
McKeever, “Insights About Brain Tumors Gained Through Immunohistochemistry and in Situ Hybridization of Nuclear and Phenotypic Markers,”J. Histochem. Cytochem., 1998, 45(5):585-594.
Mori et al., “Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-α or basic fibroblast growth factor,”J. Neuro-Oncology, 2000, 46:115-123.
Moskaug et al., “Translocation of Diphtheria Toxin A-fragment to the Cytosol,”J. Biol. Chem., 1989, 264(26):15709-15713.
Oldfield and Youle, “Immunotoxins for Brain Tumor Therapy,”Current Topics in Microbiology and Immunology, 1998, 234:97-114.
Pastan and FitzGerald, “Pseudomonas Exotoxin: Chimeric Toxins,”J. Biol. Chem., 1989, 264(26):15157-15160.
Rajagopal and Kreitman, “Recombinant Toxins That Bind to the Urokinanse Receptor Are Cytotoxic without Requiring Binding to the α2-Macroglobulin Receptor,”J. Biol. Chem., 2000, 275(11):7566-7573.
Ramakrishnan et al., “Vascular Endothelial Growth Factor-Toxin Conjugate Specifically Inhibits KDR/flk-1-positive Endothelial Cell Proliferation in Vitro and Angiogenesis in Vivo,”Cancer Res., 1996, 56:1324-1330.
Vallera et al., “Anti-Graft-Versus-Host Disease Effect of DT390-Anti-CD3sFv, a Single-Chain Fv Fusion Immunotoxin Specifically Targeting the CD3ε Moiety of the T-Cell Receptor,”Blood, 1996, 88(6):2342-2353.
Vallera et al., “Renal Dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin,”Protein Engin., 1997, 10(9):1071-1076.
Vallera et al., “Retroviral Immunotoxin Gene Therapy of Acute Myelogenous Leukemia in Mice Using Cytotoxic T Cells Transduced with an Interleukin 4/Diphtheria Toxin Gene,”Cancer Res., 2000, 60:976-984.
Hall Walter A.
Vallera Daniel A.
Canella Karen A.
Fish & Richardson P.C. P.A.
Regents of the University of Minnesota
LandOfFree
DTAT fusion toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DTAT fusion toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DTAT fusion toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3367586